Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Share Embed Flag
Download ePaper

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

pharmareview.files.wordpress.com
from pharmareview.files.wordpress.com More from this publisher
02.06.2013 Views

DISOPYRAMIDE Trade names: Dimodan; Dirythmin SA; Disonorm; Durbis; Isorythm; Norpace (Pfizer) Indications: Ventricular arrhythmias Category: Antiarrhythmic class Ia; Muscarinic antagonist Half-life: 4–10 hours Clinically important, potentially hazardous interactions with: arsenic, ciprofloxacin, clarithromycin, enoxacin, erythromycin, gatifloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, quinolones, roxithromycin, sparfloxacin Reactions Skin Angioedema Dermatitis Edema (1–3%) Erythema nodosum (1985): Niv Y+, Harefuah (Hebrew) 108, 490 Exanthems (1–5%) (1987): Brogden RN+, Drugs 34, 151 (1–2%) Lupus erythematosus (

186 DOBUTAMINE DOBUTAMINE Trade names: Cardiject; Dobril; Dobuject; Dobutamin; Dobutrex (Lilly); Inotrex; Oxiken; Tobrex Indications: Cardiac surgery, heart failure Category: Adrenergic beta-receptor agonist; Catecholamine; Inotropic sympathomimetic Half-life: 2 minutes Clinically important, potentially hazardous interactions with: furazolidone Reactions Skin Cellulitis (1994): Cernek PK, Ann Pharmacother 28, 964 Erythema (1991): Wu CC+, Chest 99, 1547 Necrosis Pruritus (1991): Wu CC+, Chest 99, 1547 (1986): McCauley CS+, AnnInternMed105, 966 (scalp) Other Hypersensitivity (1991): Wu CC+, Chest 99, 1547 Injection-site pain Injection-site phlebitis Phlebitis DOCETAXEL Trade name: Taxotere (Sanofi-Aventis) Indications: Metastatic breast cancer Category: Taxane Half-life: 11–18 hours Clinically important, potentially hazardous interactions with: aldesleukin, aprepitant, prednisone Reactions Skin Allergic reactions (sic) (2001): Talla M+, Therapie 56(5), 632 Angioedema Edema (1–20%) (2007): Tashiro H+, Gan To Kagaku Ryoho 34(3), 393 (with cyclophosphamide) (25%) (2007): Tashiro H+, Gan To Kagaku Ryoho 34(3), 453 (100%) (2004): Furugen Y+, Gan To Kagaku Ryoho 31(8), 1205 (30%) (with carboplatin) (2003): Qin YK+, Ai Zheng 22(4), 415 (2002): Eich D+, Am J Clin Oncol 25(6), 599 (passim) (1996): Edmonson JH+, Am J Clin Oncon 19, 574 (1993): Schrijvers D+, Ann Oncol 4, 610 (20%) Erythema (0.9%) (2002): Hirai K+, Gynecol Obstet Invest 53(2), 118 (1995): Cortes JE+, J Clin Oncol 13, 2643 Exanthems (1995): Cortes JE+, J Clin Oncol 13, 2643 (1995): Zimmerman GC+, Arch Dermatol 131, 202 Facial erythema (2004): Katoh M+, JDermatol31(5), 403 Fixed eruption (erythematous plaque) (2000): Chu CY+, Br J Dermatol 142, 808 Hand–foot syndrome (2006): Kara IO+, Breast 15(3), 414 (with capecitabine) (2005): Levy C+, Cancer Treat Rev 31 Suppl 4, S17 (with capecitabine) (2005): Ramanathan RK+, Cancer Chemother Pharmacol 55(4), 354 (with capecitabine) (2004): Katoh M+, JDermatol31(5), 403 (2004): Lebowitz PF+, Clin Cancer Res 10(20), 6764 (with capecitabine) (2004): Mackey JR+, Clin Breast Cancer 5(4), 287 (30%) (with capecitabine) (2004): Park YH+, Br J Cancer 90(7), 1329 (with capecitabine) (2004): Pavlick AC+, Anticancer Drugs 15(2), 119 (with doxorubicin) (2003): Han JY+, Cancer 98(9), 1918 (33%) (with capecitabine) (2002): Eich D+, Am J Clin Oncol 25(6), 599 (2 cases) (2002): O’Shaughnessy J+, J Clin Oncol 20(12), 2812 (with capecitabine) (2000): Chu CY+, Br J Dermatol 142(4), 808 (1995): Zimmerman GC+, Arch Dermatol 131, 202 (1994): Zimmerman GC+, J Natl Cancer Inst 86, 557 (1993): Vukelja SJ+, J Natl Cancer Inst 85, 1432 Lupus erythematosus (2004): Chen M+, J Rheumatol 31(4), 818 (4 cases) (subacute) Peripheral edema (2002): Koukourakis MI+, Anticancer Res 22(4), 2491 (1998): Hainsworth JD+, J Clin Oncol 16(6), 2164 (1995): Zimmerman GC+, Arch Dermatol 131, 202 Photo-recall (2005): Kandemir EG+, Swiss Med Wkly 135(1-2), 34 (2002): Magne N+, Cancer Radiother 6(5), 281 (2 cases) (2002): Morkas M+, J Clin Oncol 20(3), 867 (2002): Piroth MD+, Onkologie 25(5), 438 (2001): Giesel BU+, Strahlenther Onkol 177(9), 487 (1995): Zimmerman GC+, Arch Dermatol 101, 202 Photosensitivity (2002): Eich D+, Am J Clin Oncol 25(6), 599 (passim) (1995): Zimmerman GC+, Arch Dermatol 131, 202 Pigmentation (2005): Aydogan I+, J Eur Acad Dermatol Venereol 19(3), 345 (supravenous) Pruritus (1995): Cortes JE+, J Clin Oncol 13, 2643 Radiodermatitis (2005): Borgia F+, Br J Dermatol 153(3), 674 Rash (sic) (0.9%) (1996): Edmonson JH+, Am J Clin Oncon 19, 574 Recall reaction (2005): Chu CY+, Br J Dermatol 153(2), 441 Scleroderma (2002): Eich D+, Am J Clin Oncol 25(6), 599 (passim) (2001): Hassett G+, Clin Exp Rheumatol 19(2), 197 (2000): Cleveland MG+, Cancer 88(5), 1078 (1995): Battafarano DF+, Cancer 76, 110 Seborrheic keratoses (2001): Chu CY+, Acta Derm Venereol 81(4), 316 Squamous syringometaplasia (2002): Karam A+, Br J Dermatol 146(3), 524 Toxic epidermal necrolysis (2002): Dourakis SP+, J Clin Oncol 20(13), 3030 Toxicity (sic) (2007): Tashiro H+, Gan To Kagaku Ryoho 34(3), 393 (with cyclophosphamide) (13%) (2007): Tinker AV+, Gynecol Oncol 104(3), 647 (3%) (2003): Fracasso PM+, Cancer 98(3), 610 Urticaria (2005): Feldweg AM+, Gynecol Oncol 96(3), 824 Xerosis

DISOPYRAMIDE<br />

Trade names: Dimodan; Dirythmin SA; Disonorm; Durbis;<br />

Isorythm; Norpace (Pfizer)<br />

Indications: Ventricular arrhythmias<br />

Category: Antiarrhythmic class Ia; Muscarinic antagonist<br />

Half-life: 4–10 hours<br />

Clinically important, potentially hazardous interactions<br />

with: arsenic, ciprofloxacin, clarithromycin, enoxacin,<br />

erythromycin, gatifloxacin, lomefloxacin, moxifloxacin,<br />

norfloxacin, ofloxacin, quinolones, roxithromycin, sparfloxacin<br />

Reactions<br />

Skin<br />

Angioedema<br />

Dermatitis<br />

Edema (1–3%)<br />

Erythema nodosum<br />

(1985): Niv Y+, Harefuah (Hebrew) 108, 490<br />

Exanthems (1–5%)<br />

(1987): Brogden RN+, <strong>Drug</strong>s 34, 151 (1–2%)<br />

Lupus erythematosus (

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!